Logo image of SRDX

SURMODICS INC (SRDX) Stock Fundamental Analysis

NASDAQ:SRDX - Nasdaq - US8688731004 - Common Stock - Currency: USD

27.3  -0.27 (-0.98%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SRDX. SRDX was compared to 191 industry peers in the Health Care Equipment & Supplies industry. The financial health of SRDX is average, but there are quite some concerns on its profitability. SRDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRDX had negative earnings in the past year.
In the past year SRDX had a positive cash flow from operations.
In multiple years SRDX reported negative net income over the last 5 years.
Of the past 5 years SRDX 4 years had a positive operating cash flow.
SRDX Yearly Net Income VS EBIT VS OCF VS FCFSRDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

SRDX has a Return On Assets of -8.80%. This is in the better half of the industry: SRDX outperforms 61.78% of its industry peers.
SRDX has a better Return On Equity (-12.89%) than 64.40% of its industry peers.
Industry RankSector Rank
ROA -8.8%
ROE -12.89%
ROIC N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
SRDX Yearly ROA, ROE, ROICSRDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

SRDX has a better Gross Margin (74.77%) than 87.43% of its industry peers.
SRDX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SRDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
SRDX Yearly Profit, Operating, Gross MarginsSRDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

SRDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SRDX has more shares outstanding
SRDX has a worse debt/assets ratio than last year.
SRDX Yearly Shares OutstandingSRDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
SRDX Yearly Total Debt VS Total AssetsSRDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SRDX has an Altman-Z score of 6.32. This indicates that SRDX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.32, SRDX belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
SRDX has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SRDX (0.26) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 6.32
ROIC/WACCN/A
WACC9.28%
SRDX Yearly LT Debt VS Equity VS FCFSRDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.45 indicates that SRDX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.45, SRDX belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
SRDX has a Quick Ratio of 4.29. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
SRDX has a better Quick ratio (4.29) than 75.39% of its industry peers.
Industry RankSector Rank
Current Ratio 5.45
Quick Ratio 4.29
SRDX Yearly Current Assets VS Current LiabilitesSRDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

SRDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -156.92%.
SRDX shows a decrease in Revenue. In the last year, the revenue decreased by -9.23%.
The Revenue has been growing slightly by 4.72% on average over the past years.
EPS 1Y (TTM)-156.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-360.68%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-2.06%

3.2 Future

SRDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.52% yearly.
The Revenue is expected to grow by 3.26% on average over the next years.
EPS Next Y-14.36%
EPS Next 2Y32.97%
EPS Next 3Y45.52%
EPS Next 5YN/A
Revenue Next Year3.27%
Revenue Next 2Y1.8%
Revenue Next 3Y3.26%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRDX Yearly Revenue VS EstimatesSRDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
SRDX Yearly EPS VS EstimatesSRDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SRDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SRDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRDX Price Earnings VS Forward Price EarningsSRDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRDX indicates a somewhat cheap valuation: SRDX is cheaper than 65.44% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 59.25
SRDX Per share dataSRDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

SRDX's earnings are expected to grow with 45.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.97%
EPS Next 3Y45.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURMODICS INC

NASDAQ:SRDX (4/21/2025, 2:25:32 PM)

27.3

-0.27 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-30 2025-01-30/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners86.57%
Inst Owner Change-0.04%
Ins Owners3.35%
Ins Owner Change-1.47%
Market Cap390.12M
Analysts77.78
Price Target43.86 (60.66%)
Short Float %1.97%
Short Ratio0.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.66%
Min EPS beat(2)56.65%
Max EPS beat(2)66.67%
EPS beat(4)4
Avg EPS beat(4)66.14%
Min EPS beat(4)19.79%
Max EPS beat(4)121.45%
EPS beat(8)8
Avg EPS beat(8)180.31%
EPS beat(12)12
Avg EPS beat(12)130.07%
EPS beat(16)15
Avg EPS beat(16)104.81%
Revenue beat(2)1
Avg Revenue beat(2)-2.45%
Min Revenue beat(2)-12.08%
Max Revenue beat(2)7.17%
Revenue beat(4)2
Avg Revenue beat(4)0.71%
Min Revenue beat(4)-12.08%
Max Revenue beat(4)8.62%
Revenue beat(8)6
Avg Revenue beat(8)5.82%
Revenue beat(12)9
Avg Revenue beat(12)4.75%
Revenue beat(16)12
Avg Revenue beat(16)3.66%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)19.05%
EPS NQ rev (3m)-30.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-54.17%
Revenue NQ rev (1m)-2.89%
Revenue NQ rev (3m)-8.59%
Revenue NY rev (1m)-3.29%
Revenue NY rev (3m)-9.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF 340.42
P/B 3.49
P/tB 8.11
EV/EBITDA 59.25
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.08
OCFY0.29%
SpS8.78
BVpS7.82
TBVpS3.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.8%
ROE -12.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.77%
FCFM N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
F-Score3
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA 4.46
Cap/Depr 36.4%
Cap/Sales 2.45%
Interest Coverage N/A
Cash Conversion 17.26%
Profit Quality N/A
Current Ratio 5.45
Quick Ratio 4.29
Altman-Z 6.32
F-Score3
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)37.09%
Cap/Depr(5y)48.03%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-156.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-360.68%
EPS Next Y-14.36%
EPS Next 2Y32.97%
EPS Next 3Y45.52%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-2.06%
Revenue Next Year3.27%
Revenue Next 2Y1.8%
Revenue Next 3Y3.26%
Revenue Next 5YN/A
EBIT growth 1Y-113.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year223.25%
EBIT Next 3Y62.57%
EBIT Next 5YN/A
FCF growth 1Y92.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y105.46%
OCF growth 3Y-74.74%
OCF growth 5Y-50.13%